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Abstract
Background: Previous investigations suggest the use of extract from the roots of
Pelargonium sidoides (EPs 7630) for the therapy of uncomplicated rhinosinusitis. The
aim of this prospective study was to compare the effects of herbal drug EPs 7630
and antibiotic roxithromycin on chemokine production in nasal mucosa and clinical
parameters in patients with uncomplicated acute bacterial rhinosinusitis (ABRS).
Methods: Seventy-eight ABRS patients were divided into 26 patients receiving EPs
7630 tablets, 3 × 20 mg/day per os (group 1), 26 patients receiving roxithromycin
tablets, 2 × 150 mg/day per os (group 2), both for 10 days, and 26 patients who
received no therapy (Control group). We measured chemokine levels in nasal secre-
tions by flow cytometry and assessed clinical parameters on day 0 and day 10 of
investigation.
Results: EPs 7630 increased concentrations of MCP-1 (P = .001) and IP-10 (P = .049)
and decreased levels of MIP-1α (P < .001), ENA-78 (P < .001), and IL-8 (P < .001).
Roxithromycin increased levels of IP-10 (P = .049) and decreased levels of MCP-1
(P < .001), MIP-1α (P < .016), ENA-78 (P < .001), and IL-8 (P < .001). Comparison of
the non-treated patients' group with groups 1 and 2 revealed significant improve-
ment of all clinical parameters in treated patients (P < .001), but therapy with
Abbreviations: ENA-78, epithelial-neutrophil activating peptide; GROα, growth-regulated alpha protein precursor; IL-8, interleukin 8; IP-10, interferon gamma-induced protein 10; I-TAC,
interferon inducible T-cell alpha chemoattractant; MCP-1, monocyte chemoattractant protein 1; MIG, monokine induced by gamma interferon; MIP-1α, macrophage inflammatory protein
1 alpha; MIP-1β, macrophage inflammatory protein 1 beta; MIP-3α, macrophage inflammatory protein 3 alpha; RANTES, regulated on activation, normal T-cell expressed and secreted; TARC,
thymus and activation regulated chemokine.
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roxithromycin resulted in better improvement in nasal symptoms and endoscopic
findings than therapy with EPs 7630.
Conclusion: Our results suggest the presence of similar modulatory effects of both
therapies on production of chemokines that regulate the function of neutrophils and
monocytes in nasal mucosa. Roxithromycin shows better clinical efficacy than EPs
7630 in patients with uncomplicated ABRS.
Level of Evidence: 1b.
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1 | INTRODUCTION
Acute rhinosinusitis (ARS) is an inflammation which suddenly affects
the mucosa of the nasal cavity and paranasal sinuses. Viral ARS usually
passes for 10 days with or without symptomatic therapy, or can be
complicated by secondary bacterial infection that requires antimicro-
bial therapy.1,2 Symptoms of acute bacterial rhinosinusitis (ABRS) are
caused by infection-stimulated production of inflammatory media-
tors.1,2 In most cases, the acute suppurative infection resolves
promptly following a course of antibiotic therapy supplemented with
adjuvant therapy of decongestants, antihistamines, and intranasal cor-
ticosteroid sprays.3,4 However, the role of inflammatory mediators in
ABRS is not explored in detail. Bacterial infection of the nasal mucosa
stimulates the production and release of variety of cytokines and
chemokines in the respiratory epithelial cells.1,5 This bacterial infec-
tion induces multiple changes in the nasal mucosa, including infiltra-
tion and activation of various inflammatory cells, especially
neutrophils and monocytes and defects in the host and adaptive
immune defence functions.1,5
Macrolide antibiotics, for example, erythromycin, clarithromycin,
azithromycin and roxithromycin, are well-known for decades as a
good option in therapy of acute and chronic rhinosinusitis due to
strong bacteriostatic and immunomodulatory effects.1,4,5 They bind to
the 50S subunits of the bacterial ribosome, inhibiting protein
synthesis.1,5
Herbal medicines have been used for centuries for therapy of
acute upper airway infections. Preparation from the roots of Pelargo-
nium sidoides was used for generations in South Africa for treatment
of respiratory and gastrointestinal infections, due to its antiviral and
antibacterial actions.6 More than seven decades later, this
polyphenol-rich extract was finally developed in Germany with coding
name EPs 7630.6 According to the International Consensus Statement
on Allergy & Rhinology: Rhinosinusitis and European Position Paper
on Rhinosinusitis and Nasal Polyps (EPOS) 2020, the use of extract
from Pelargonium sidoides is recommended as an option in therapy of
ARS.1,5 The immunomodulatory effects of this herbal drug are medi-
ated mainly by stimulation of tumor necrosis factor alpha (TNF-α),
interferon beta (IFN-β), IFN-γ and interleukin-10 (IL-10) production
and reducing production of IL-6 and IL-15 in human respiratory tract
epithelial cells.6-10 Intensity of inflammatory reaction during the ARS
depends on action of chemokines, small cytokines that attract differ-
ent inflammatory cells to the site of infection.
However, in vivo studies related to the effects of EPs 7630 on
chemokine production in nasal mucosa of patients with ABRS were
not previously conducted. This study is designed to compare the
effects of therapy by EPs 7630 and macrolide antibiotic roxithromycin
on chemokine production in nasal mucosa, as well as on clinical
parameters of patients with mild-to-moderate ABRS.
2 | PATIENTS AND METHODS
2.1 | Study design and ethical considerations
This randomized, open label, noninferiority, prospective study was
conducted from May 2019 to November 2020. The protocol for
investigation is approved by the Institutional Review Board of the Mil-
itary Medical Academy, Belgrade, Serbia (Ethics Committee Approval
No. 05/2019) and this study is registered as a part of Projects of the
Military Medical Academy, Belgrade, Serbia (MFVMA02/19-21/) and
the Ministry of Education, Science and Technology of the Republic of
Serbia (No. III45005). Written informed consent was obtained from
each patient.
2.2 | Study participants
Seventy-eight (n = 78) adult patients with mild-to-moderate ABRS
were enrolled in this investigation. Diagnosis of ABRS was made
according to the criteria of the updated Clinical Practice Guideline for
adult sinusitis, published by American Academy of Otolaryngology
Head & Neck Surgery.2 Patients had diagnosis of ABRS if:
(a) symptoms (nasal obstruction, anterior nasal secretion/postnasal
drip, facial pain/pressure, and/or impaired or loss of the sense of
smell) or signs of ARS (mucosal edema, mucopurulent secretion) per-
sist without evidence of improvement for at least 10 days beyond the
onset of upper respiratory symptoms or (b) symptoms or signs of ARS
were worsen within first 10 days after an initial improvement. To
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confirm the diagnosis of ABRS, aspirate from middle meatus was
taken from every patient and samples were cultivated on Blood Agar
(HiMedia Laboratories, Mumbai, India).
Exclusion criteria were: <18 years or >65 years, nasal/paranasal
sinus surgery within 6 months before study, systemic diseases (cystic
fibrosis, Churg Strauss syndrome, Wegener's granulomatosis, etc.),
symptomatic seasonal allergic rhinitis (after pollen exposure during
the study), bronchial asthma, hypersensitivity to roxithromycin or to
Pelargonium sidoides extract, patients taking anticoagulants and salicy-
lates, patients with gastrointestinal and hepatobiliary diseases, the use
of oral or topical antibiotics, antihistamines and corticosteroids within
the 4 weeks before the start of the study, the use of mucolytic,
decongestants and hypertonic seawater within the 7 days before the
investigation, pregnancy, lactation, active cigarette smoking. Subjects
were excluded if they had symptoms or signs of severe acute bacterial
rhinosinusitis (fever > 38C, persistent severe unilateral facial or tooth
pain, facial swelling, profuse unilateral mucopurulent secretion and
worsening of symptoms after initial improvement).
2.3 | Randomization
The randomization was performed in accordance with the CONSORT
statement. A hundred patients (n = 100) with mild-to-moderate ABRS,
examined and treated in our ENT Department, were involved in the
study. Seven (n = 7) refused to participate while 15 (n = 15) patients
did not meet inclusion criteria. Seventy-eight (n = 78) patients were
thus recruited and assigned to the group 1 (n = 26), group 2 (n = 26),
and control group (n = 26) by randomization. We used a simple
computer-generated randomization procedure to allocate the partici-
pants into groups. The participants were deemed eligible by the inves-
tigator who informed the nurse about the eligibility. The nurse than
assigned the patient to group 1, 2 and control group using a
computer-generated random allocation. The study profile is presented
in Figure 1.
2.4 | Treatment
The ABRS patients from group 1 received herbal drug EPs 7630 oral
tablets 3 × 20 mg/day (Umckalor, Dr. Willmar Schwabe GmbH &
Co. KG, Karlsruhe, Germany), 10 days in total. The patients from
group 2 received roxithromycin oral tablets 2 × 150 mg/day
(Roximisan, Slaviamed, Belgrade, Serbia), also for 10 days. The
patients with control group did not receive any medication and all the
patients with severe deterioration in nasal symptoms or endoscopic
findings were excluded from further investigation. Both the investiga-
tors and the patients were aware of the drug being given or not given.
The patients did not use other medications simultaneously with herbal
drug/roxithromycin.
F IGURE 1 Randomization of
study participants. One hundred
patients (n = 100) with diagnosis
of ABRS were selected to
participate in the study. Five
(n = 7) refused to participate and
eleven (n = 15) patients did not
meet inclusion criteria. Seventy-
eight (n = 78) patients were finally
recruited and assigned by
randomization to the group
1 (n = 26) and group 2 (n = 26)
and control group (n = 26)
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2.5 | Detection of chemokines
Nasal fluid samples were obtained from all 78 ABRS patients, at the
beginning of the study (day 0, visit 1) and again at day 10 (visit 2) after
the start of study by absorption method. After the insertion of cotton
wool stick (Institute for Virology, Vaccines and Sera, “Torlak,”
Belgrade, Serbia) into the nasal middle meatus for 5 minutes, as previ-
ously described,11 the stick watered with nasal fluid was put in a 2 mL
tube, which contained 1 mL of transfer medium (two antibiotics and
one antimycotic in phosphate-buffered saline). It takes about
30 minutes for diffusion of mediators into the medium. After centrifu-
gation of samples for 10 minutes and cell separation, the supernatants
were frozen at −70C, until mediator determination. The measure-
ment of 13 chemokines (MCP-1, RANTES, IP-10, eotaxin, TARC,
MIP-1α, MIP-1β, MIG, MIP-3α, ENA-78, GROα, I-TAC and IL-8) in
nasal secretions of ABRS patients was done on a Flow Cytometer
(NAVIOS, Beckmann Coulter, Brea, California), using human bead-
based multiple mediator detection commercial kit for chemokines
(LEGEND plex, Bio Legend, San Diego, California). The levels of
chemokines were expressed in picograms/milliliters (pg/mL). The sen-
sitivities of detection, assay range and coefficients of variation for bio-
chemical parameters are presented in Table 1.
2.6 | Clinical evaluation
Total symptom score (TSS), the sum of intensities of 5 rhinosinusitis
symptoms (nasal obstruction, rhinorrhea, postnasal drip, facial pain/
pressure, loss of the sense of smell), as well as individual scores for
each nasal symptom were assessed at the visit 1 and visit 2 by the
same specialist, using a visual analogue scale (VAS) (0-10 cm;
0 = absent, 10 = maximum intensity). Patients indicated their symp-
toms' score to be from 0 to 3 were diagnosed as “mild ARS.” Symp-
toms in the score range from 4 to 7 were diagnosed as “moderate
ARS”, while the scores from 8 to 10 with fever of above 38C for at
least 3 days were diagnosed as “severe ARS.” The patients with
severe disease were excluded from investigation. During the investi-
gation, patients recorded their symptom scores and noted the use of
medications on diary cards and the investigator recorded scores at the
visit 2. The investigator evaluated compliance of the treatment by
insight into the diary cards. TSS of control subjects was also assessed.
At visits 1 and 2, an experienced rhinologist evaluated the presence
of mucosal edema and secretion in the middle meatus by use of nasal
endoscopy (4 mm 0 endoscope, Karl Storz—Endoscope SE & Co,
Tuttlingen, Germany). Four-point scales were used for assessment of
endoscopic findings, according to the Pfaar et al.12 Mucosal edema scored
from 0 (no edema) to 3 (severe edema); middle meatus secretion from
0 (none) to 3 (profuse). The maximum Total Endoscopic Score (TES) was
12, bilaterally. According to the current guidelines, radiological examina-
tions (X-ray, CT, MRI) were not used in the diagnostics of ABRS.1,2
2.7 | Safety
Reported adverse events were recorded throughout the study, with
severity grades as mild, moderate and severe. At visit 2, nasal examina-
tion, laboratory tests and vital signs assessment were performed. All
patients were aware of potential adverse effects of herbal medication or
roxithromycin. Therefore, the development of any medical complica-
tions associated with progression of ABRS (orbital, endocranial or bone
complications) was also recorded during the study.
2.8 | Strength of the study and statistical analysis
We performed a power analysis with the use of the G*Power 3.1.9 pro-
gramme (Heinrich Heine Univerität, Düsseldorf, Germany). For the
effect size of 0.4 the type I error (α level) .05, the power of 80%, and
the comparison of three groups with two measurements for each group,
a total of 66 participants was calculated (22 per group). We calculated a
TABLE 1 Sensitivity of detection,
assay range and coefficient of variation
for investigated mediators
Mediator Sensitivity of detection (pg/mL) Assay range (pg/mL) Coefficient of variation (%)
MCP-1 0.9 159.8-3488.4 6
RANTES 4.3 188.2-19 563.0 5
IP-10 1.1 37.3-636.9 5
Eotaxin 1.4 ND-378.6 7
TARC 0.8 20.4-151.3 4
MIP-1α 2.1 7.0-1999.7 4
MIP-1β 1.4 6.1-195.4 4
MIG 9.4 ND- 420.8 9
MIP-3α 2.5 6.7-155.2 4
ENA-78 1.1 12.5-935.4 7
GROα 6.7 ND-1550.9 3
I-TAC 1.1 8.1-139.1 6
IL-8 1.4 11.5-7636.4 8
Abbreviation: ND, nondetectable.
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drop-out rate of 20% and therefore included 26 patients in each group.
The parameters were expressed as mean ± SD. For comparison
between the groups, the non-parametric Kruskal-Wallis test was used. If
the test revealed significant difference among groups the Mann-
Whitney U test was further used to detect differences between groups.
For paired comparisons in a group, we used the Wilcoxon's test. To cal-
culate the relative changes of each parameter, we used the formula:
posttherapeutic value—pretherapeutic value/pretherapeutic value.
P values < .05 were considered significant. No adjustments for
multiplicity were applied. The analysis was done by using the Statistical
Package for the Social Sciences, version 15.0 software (SPSS Inc., Chi-
cago, Illinois).
3 | RESULTS
Baseline demographic characteristics of ABRS patients after randomi-
zation are presented in Table 2. Clinical parameters at visit 1 and visit
TABLE 2 Baseline demographic characteristics of ABRS patients, after randomization. They were divided into patients without treatment,
patients treated by EPs 7630 and those treated by roxithromycin
Parameter Without treatment (n = 26) EPs 7630 (n = 26) Roxithromycin (n = 26) P value
Male/female 14/12 14/12 14/12 1.000







TABLE 3 Presentation of clinical parameters at visit 1 and visit 2
Parameter
Controls (n = 26)
Mean ± SD (range)
EPs 7630 (n = 26)
|Mean ± SD (range)
Roxithromycin (n = 26)




Visit 1 6.5 ± 0.6 (5-7) 6.5 ± 0.6 (5-7) 6.5 ± 0.6 (5-7) .975
Visit 2 6.9 ± 0.3 (5-7) 3.1 ± 0.4 (2-4) 2.1 ± 0.7 (2-3) <.001
RH
Visit 1 6.4 ± 0.9 (4-7) 6.5 ± 0.6 (5-7) 6.6 ± 0.5 (6-7) .768
Visit 2 6.9 ± 0.3 (6-7) 3.4 ± 0.8 (2-5) 3.5 ± 0.8 (2-5) <.001
PD
Visit 1 6.6 ± 0.6 (5-7) 6.4 ± 0.6 (5-7) 6.5 ± 0.6 (5-7) .624
Visit 2 6.8 ± 0.4 (6-7) 3.0 ± 0.6 (2-4) 2.9 ± 0.7 (2-5) <.001
FPP
Visit 1 6.5 ± 0.8 (5-7) 6.5 ± 0.5 (6-7) 6.7 ± 0.7 (4-7) .147
Visit 2 6.6 ± 0.6 (6-7) 3.0 ± 0.3 (2-4) 2.1 ± 0.6 (2-4) <.001
LSS
Visit 1 6.4 ± 0.8 (5-7) 6.6 ± 0.6 (5-7) 6.4 ± 0.6 (5-7) .384
Visit 2 6.8 ± 0.5 (6-7) 3.1 ± 0.5 (2-3) 2.0 ± 0.6 (1-3) <.001
TSS
Visit 1 32.3 ± 2.0 (29-35) 32.5 ± 1.6 (28-35) 32.7 ± 1.8 (29-35) .701
Visit 2 34.0 ± 1.0 (32-35) 15.9 ± 1.2 (12-20) 12.3 ± 2.0 (10-15) <.001
TES
Visit 1 10.6 ± 1.0 (9-12) 10.9 ± 0.9 (9-12) 10.4 ± 0.8 (9-12) .085
Visit 2 11.8 ± 0.4 (11-12) 5.9 ± 0.7 (5-7) 3.8 ± 0.7 (3-5) <.001
ME
Visit 1 5.3 ± 0.8 (4-6) 5.8 ± 0.4 (5-6) 5.6 ± 0.5 (5-6) .046
Visit 2 5.8 ± 0.4 (5-6) 2.9 ± 0.4 (2-4) 2.1 ± 0.5 (2-3) <.001
MS
Visit 1 5.3 ± 0.8 (4-6) 5.2 ± 0.7 (4-6) 4.8 ± 0.7 (4-6) .102
Visit 2 5.9 ± 0.3 (4-6) 3.0 ± 0.6 (2-4) 1.8 ± 0.5 (1-3) <.001
Abbreviations: FPP, facial pain/pressure; LSS, loss of sense of smell; ME, mucosal edema; MS, mucopurulent secretion; NO, nasal obstruction; PD,
postnasal drip; RH, rhinorrhea; TES, total endoscopic score; TSS, total symptom score.
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2 are presented in Table 3. We found no improvement in symptoms
and endoscopic findings in non-treated patients' group. After the both
treatment modalities, we found significant improvement in all symp-
toms and endoscopic findings (P < .001). However, patients treated
by roxithromycin had better relative improvement (P < .001) for all
clinical parameters, except for rhinorrhea (P = .197) and postnasal drip
score (P = .642) (Table 4).
Chemokine concentrations in nasal secretions at visit 1 and visit
2 are presented in Table 5. The inflammatory mediator levels in non-
treated patients are increased at visit 2, except for RANTES and
GROα. After the therapy by EPs 7630, the concentrations of MCP-1
and IP-10 were significantly higher (P = .001; P = .049, respectively)
and levels of MIP-1α, ENA-78, and IL-8 were significantly lower
(P < .001; P < .001; P < .001, respectively). After the roxithromycin
therapy, we found increased concentration of IP-10 (P = .049) and
decreased levels of MCP-1, MIP-1α, ENA-78, and IL-8 (P < .001;
P = .016; P < .001; P < .001, respectively). The concentration of MIP-
1β increase after the therapy by herbal drug and decrease after the
roxithromycin therapy, but it was a difference that was close to a level
of statistical significance (P = .057) (Table 5).
Regarding the relative changes of chemokine levels, treatment by
EPs 7630 resulted in bigger increase of IP-10 (P < .001) and bigger
decrease of MIP-1α, ENA-78, and IL-8 (P < .001; P < .001; P < .037,
respectively) (Figure 2).
No adverse events were noted during the therapy by EPs 7630
and roxithromycin.
4 | DISCUSSION
Inflammatory mediator-related investigations in patients with ABRS
have rarely been performed and our study is the first one which evalu-
ated the chemokine production by nasal mucosa during the therapy
with Pelargonium sidoides extract. According to previous investiga-
tions, contents of nasal secretions reflects the inflammatory status of
the nasal mucosa and evolution of mucosal disease.14-16 Nasal epithe-
lial cells elicit their own repertoire of immune responses and actively
prevent pathogens from damaging the airway. Upon viral and bacterial
infection, nasal epithelium release not only anti-microbial surfactants
and mucus to delay pathogen transmission in the airway, but also
secrete various cytokines and chemokines to drive immune responses
against invading pathogens.1-5 Bacterial infection of respiratory epi-
thelium leads to an increased production of cytokines (IFN-β, IFN-γ,
IL-1β, TNF-α, and IL-6) and chemokines (IL-8, IP-10, I-TAC,
etc.).1,5,13-15
Many different mechanisms of macrolide antibiotics immunomod-
ulatory effects have been described throughout the literature. Effects
have been reported on airway secretions, inflammation, and direct
effect on bacteria. The many different actions of macrolide antibiotics
on cellular function, including airway epithelial cells, neutrophils,
eosinophils, lymphocytes, monocytes, macrophages, fibroblasts, and
vascular endothelial cells have been described.16 The epithelial cells
demonstrated a decrease in mucin secretion and expression of inflam-
matory cytokines after the therapy by roxithromycin.17 Relaxation in
smooth muscle cells, inhibition of IL-8 production and release, and
decreases in fibroblast growth factors are also seen with macrolide
use in in vitro studies.5,16,17
Herbal drug EPs 7630 showed many actions against viral and bac-
terial infections. It increases ciliary beat frequency (CBF) of an adher-
ent monolayer culture of human nasal epithelial cells.6 This drug
demonstrates effects against influenza and parainfluenza virus, respi-
ratory syncytial virus, and, especially, human coronavirus by inhibitory
action of herbal bioflavonoids and polyphenols against enzyme neur-
aminidase, very important in viral replication6,7 In a controlled ran-
domized study, Bachert et al.8 found EPs 7630 to be well tolerated
and superior in efficacy compared to placebo in the treatment of
ARS of bacterial origin. Significant and clinically relevant benefits of
treatment by this herbal medicine were already evident after 7 days
of treatment.8 EPs 7630 has direct effect against a spectrum of
Gram-positive and Gram-negative bacteria by stimulating non-
specific immune response.8,9 This mode of actions includes
inhibition of bacterial adhesion to epithelial cells, stimulation of
phagocytosis, nitric oxide (NO) release, and oxidative burst.8,9
Immunomodulatory actions of this drug are also interesting. A large
body of evidence indicates that induction of non-specific host
defence mechanisms against a number of pathogens, especially
TABLE 4 Comparison of relative improvement of clinical parameters after two different treatment regimens (Mann-Whitney U test)
Clinical parameters Control group** (%) EPs 7630 (%) Roxithromycin (%) P value EPs 7630/Roxithromycin
Nasal obstruction 7.1 ± 13.4 −51.2 ± 11.9 −66.3 ± 7.5 <.001
Rhinorrhea 10.2 ± 19.3 −48.7 ± 10.7 −52.7 ± 13.7 .197
Postnasal drip 4.2 ± 14.7 −52.4 ± 9.6 −56.3 ± 9.1 .642
Facial pain/pressure 4.2 ± 17.7 −53.9 ± 8.3 −67.7 ± 4.9 <.001
Loss of the sense of smell 7.9 ± 17.6 −49.9 ± 9.0 −69.7 ± 7.2 <.001
Total symptom score 5.3 ± 6.7 −51.4 ± 5.5 −62.7 ± 3.7 <.001
Total endoscopic score 11.6 ± 9.5 −44.2 ± 8.0 −64.7 ± 5.5 <.001
Mucosal edema 11.9 ± 17.9 −49.7 ± 10.3 −63.1 ± 6.2 <.001
Mucopurulent secretion 14.9 ± 18.7 −36.7 ± 14.4 −66.2 ± 10.3 <.001
**Comparison of the control group with EPs® 7630 or Roxithromycin revealed P < .001 for all parameters.
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bacteria and viruses, is related to the production of IFN-β and IFN-γ.
Previous in vitro investigations demonstrated an up-regulation of
these cytokines, as well as TNF-α after the stimulation of human
macrophages, lymphocytes and epithelial cells with Pelargonium
sidoides extract.6-9
We found significant improvement for all symptoms and endo-
scopic findings in our patients after the use of this herbal medicine.
However, these clinical effects were better in patients treated by
roxithromycin, except for the rhinorrhea and postnasal drip. This find-
ing suggests that roxithromycin and EPs 7630 almost equally suppress
TABLE 5 Presentation of chemokine concentrations at visit 1 and visit 2
Parametera
Without treatment (n = 26)
Mean ± SD (range)
EPs 7630 (n = 26)
Mean ± SD (range)
Roxithromycin (n = 26)




Visit 1 347.8 ± 277.4 465.3 ± 314.1 493.1 ± 328.4 .015
Visit 2 414.8 ± 314.2 598.3 ± 327.3 311.8 ± 205.6 <.001
RANTES
Visit 1 990.3 ± 1138.9 938.9 ± 1107.7 884.5 ± 1102.2 .935
Visit 2 604.4 ± 409.8 902.8 ± 1038.9 824.2 ± 984.7 .911
IP-10
Visit 1 128.4 ± 78.4 199.8 ± 155.4 208.8 ± 148.9 .160
Visit 2 296.0 ± 636.0 307.6 ± 179.4 289.9 ± 161.1 .049
Eotaxin
Visit 1 13.0 ± 12.1 23.1 ± 37.8 31.9 ± 44.1 .667
Visit 2 14.7 ± 13.6 26.5 ± 50.0 19.6 ± 18.4 .587
TARC
Visit 1 8.7 ± 14.9 10.9 ± 17.4 6.6 ± 14.0 .840
Visit 2 101 ± 18.2 10.8 ± 19.5 4.3 ± 11.9 .885
MIP 1α
Visit 1 504.6 ± 381.7 703.6 ± 265.6 622.8 ± 369.7 .008
Visit 2 668.3 ± 433.1 375.5 ± 166.8 451.8 ± 258.8 .016
MIP 1β
Visit 1 49.3 ± 53.9 62.9 ± 31.4 64.5 ± 32.7 .007
Visit 2 63.0 ± 57.4 73.0 ± 32.0 56.1 ± 24.4 .057
MIG
Visit 1 1.1 ± 3.4 0.5 ± 1.5 0.6 ± 1.7 .860
Visit 2 1.7 ± 4.2 0.6 ± 1.7 0.8 ± 2.0 .542
MIP 3α
Visit 1 33.8 ± 34.9 56.6 ± 29.1 58.4 ± 30.9 <.001
Visit 2 40.1 ± 35.5 55.8 ± 26.9 55.6 ± 26.9 .008
ENA-78
Visit 1 207.2 ± 159.5 335.6 ± 150.8 322.8 ± 145.7 .008
Visit 2 558.8 ± 376.6 142.4 ± 98.8 232.4 ± 131.8 <.001
GROα
Visit 1 44.5 ± 51.5 153.1 ± 243.3 158.9 ± 233.3 .620
Visit 2 42.9 ± 63.7 162.1 ± 114.4 102.7 ± 154.1 .506
I-TAC
Visit 1 11.4 ± 19.7 20.3 ± 33.4 25.2 ± 43.7 .590
Visit 2 13.6 ± 23.3 17.4 ± 32.0 26.0 ± 51.1 .883
IL-8
Visit 1 596.5 ± 621.7 589.8 ± 518.7 640.3 ± 539.6 .597
Visit 2 862.5 ± 618.9 224.5 ± 157.6 415.5 ± 392.3 <.001
aConcentrations of inflammatory mediators in nasal secretions are expressed in pg/mL.
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the production and stimulate the elimination of mucus. In non-treated
patients from the control group, we found no improvement in clinical
parameters, suggesting the conclusion that in ABRS patients we can-
not expect the spontaneous resolution of symptoms and local find-
ings. Therefore, the concentrations of almost all inflammatory
mediators in patients from the control group found to be increased
during the 10 days. On the other hand, our results suggest that ther-
apy of ABRS patients by EPs 7630 stimulates MCP-1 and IP-10 and
inhibits MIP-1α, ENA-78, and IL-8 production in the nasal and sinus
mucosa. On the other hand, we found that therapy by roxithromycin
significantly increased levels of IP-10 and decreased levels of MCP-1,
MIP-1α, ENA-78, and IL-8 in nasal secretions. The concentration of
MIP-1β increase after the therapy by herbal drug and decrease after
the roxithromycin therapy, but it was a difference that was close to a
level of statistical significance. MCP-1 is secreted by monocytes and
macrophages and this chemokine exhibits chemotactic activity for
monocytes, basophils and eosinophils, but it does not attract neutro-
phils.18 IP-10 is secreted by several cell types (monocytes, endothelial
cells, and fibroblasts) in response to IFN-γ action. This mediator has
been attributed to several roles, such as chemoattraction for mono-
cytes, macrophages, T-cells and natural killer cells, all very important
in defence against pathogens.18 Both MCP-1 and IP-10 have func-
tions mainly connected to monocyte actions.18 On the other hand,
ENA-78 and IL-8 are chemokines related to function of neutrophils
and they are produced by nasal epithelial cells, monocytes and macro-
phages following stimulation of these cells with pro-inflammatory
cytokines IL-1β and TNF-α.19 These chemokines stimulate the chemo-
taxis of neutrophils to the site of inflammation caused by bacterial
infection.19,20 MIP-1α and MIP-1β are strong pro-inflammatory
chemokines, well known as chemoattractants for neutrophils, mono-
cytes, as well as eosinophils in patients with acute and chronic upper
airway inflammations.21 With respect to different effects on MCP-1
and IL-1β production in nasal mucosa, our results suggest the pres-
ence of similar modulatory actions of two drugs on monocyte and
neutrophil functions in ABRS patients. Although neutrophils have pro-
tective functions against bacterial infections, a recent in vitro study,
conducted by Kao et al.22 demonstrated that serine proteases,
enzymes derived from neutrophils showed detrimental effects on the
mucosal epithelial barrier integrity with increased permeability, all-
owing for potential bacterial infection. Accordingly, we speculate that
reduction of neutrophil chemokines by Pelargonium sidoides and
roxithromycin leads to reduced attraction of neutrophils and produc-
tion of neutrophil proteases, resulting in better protection and stabili-
zation of nasal respiratory epithelium.
According to our results, none of the patients reported adverse
events. However, there have been reports of allergic reactions, liver
toxicity and hemorrhage after treatment with Pelargonium sidoides
extract.23,24 There is a theoretical risk of interactions with anticoagu-
lants such as warfarin, and antiplatelet drugs such as aspirin. There are
also cautions against use of the tested substance by patients with
serious liver diseases or during pregnancy.23,24 Allergic reactions and
gastrointestinal symptoms are main side effects after the use of mac-
rolide antibiotics.5,17
This study has some limitations. It was an open label study based
on the assessment of symptoms and endoscopic findings. Therefore,
due to our financial limitations, we performed only biochemical
F IGURE 2 Relative changes in nasal secretion concentrations of chemokines MCP-1, IP-10, MIP-1α, MIP-1β, ENA-78, and IL-8 between visit
1 and visit 2
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analyses of chemokine profile in nasal fluid, but not a polymerase
chain reaction (PCR) analysis of nasal and sinus mucosa regarding the
capacity for production of these chemokines.
5 | CONCLUSION
According to our results, Pelargonium sidoides extract and roxithromycin
have similar modulatory effects on activation and migration of mono-
cytes and neutrophils to the site of acute inflammation. Both drugs sig-
nificantly improve symptoms and endoscopic findings in patients with
uncomplicated ABRS. However, roxithromycin provides better clinical
improvement relative to EPs 7630, except for postnasal drip and
rhinorrhea as there was a non-statistically significant difference.
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Peric AV, Vojvodic D. Effects of Pelargonium sidoides extract vs
roxithromycin on chemokine levels in nasal secretions of
patients with uncomplicated acute rhinosinusitis. Laryngoscope
Investigative Otolaryngology. 2021;6:25–33. https://doi.org/
10.1002/lio2.514
PERIC ET AL. 33
